ArticleScientific reports2025
Analysis of cellular responses following interaction with extracellular vesicles derived from HEK293T and human adipose derived stem cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exosome Biogenesis: Meta-Analysis of Intraluminal Vesicle Size Across Species.International journal of molecular sciences · 2026Pooled it
- Extracellular Vesicles in Myocardial Infarction: Dual Role in Ferroptosis Regulation and In Vivo Imaging.Diagnostics (Basel, Switzerland) · 2026Review
- Microfluidic engineering of pDNA nanogels in a coaxial flow reactor: process development, optimisation, scalability andNanoscale advances · 2026Article
- Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes.Frontiers in cellular and infection microbiology · 2026Article
- Systematic characterization of mammalian extracellular vesicles using nano-flow cytometry.Extracellular vesicle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Extracellular vesicles (EVs), particularly exosomes, are crucial mediators of intercellular communication that influence immune responses, cell proliferation, and angiogenesis. Their therapeutic potential has been explored for the treatment of chronic, non-healing wounds, especially in diabetic patients with chronic inflammation, impaired cellular proliferation, and poor angiogenesis. We investigated the role of exosomes derived from human embryonic kidney 293T (HEK293T) cells and human adipose-derived stem cells (hADSCs) on NIH3T3 fibroblast migration. Exosomes were characterized for size, concentration, and surface markers. Western blotting and scratch assays were used to assess ERK1/2 activation and cell migration. Characterization revealed that HEK293T exosomes were more abundant (3.1 × 10¹¹ ± 4.9 × 10⁹ particles/mL), larger (178 ± 4 nm), and exhibited stronger surface marker protein expression than exosomes from hADSCs (2.4 × 10⁹ ± 4.1 × 10⁸ particles/mL, 153 ± 5 nm). Both types of exosomes significantly enhanced NIH3T3 fibroblast migration with migration indices of 63.2 ± 4.3% and 48.9 ± 2.7% via ERK1/2 signaling, with HEK293T exosomes showing stronger effects because of their higher protein content. Western blot analysis revealed that robust ERK1/2 activation by both exosome types was crucial for fibroblast migration, with scratch assays highlighting their pro-migratory effects. Inhibition of the ERK1/2 pathway significantly reduced migration, with HEK293T exosomes showing a reduction to 9.6 ± 3.2% and hADSC exosomes to 2.6 ± 0.2% when treated with the MEK1/2 inhibitor PD98059. HEK293T exosomes induced more pronounced cell migration, and hADSC exosomes showed improved efficacy under stress, suggesting that both exosome types are promising candidates for targeted regenerative therapies in chronic wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.